Loading...
Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy
The treatment armamentarium for metastatic castration-resistant prostate cancer (mCRPC) has increased significantly over the past several years. Approved drugs associated with improved survival include androgen pathway-targeted agents (abiraterone acetate and enzalutamide), chemotherapeutics (doceta...
Saved in:
| Published in: | Ther Adv Urol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
SAGE Publications
2015
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4580096/ https://ncbi.nlm.nih.gov/pubmed/26445599 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287215592288 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|